In both the CREDENCE and DAPA-CKD trials and the previous CVOTs [34,35], the SGLT2 inhibitors have been reported to decrease albuminuria by approximately 30% in patients with T2D (Table 1) [36,37,38]. Here, SLC5A2 is linked to chronic kidney disease.